Despite of the good efficacy of biologic agents such as TNF-α or IL-1β blocker for many patients with rheumatoid arthritis, augmented risk of some adverse side effects such as infection [34] and malignancy [35] still persist in concern. The gene discussed is IL1B; the disease is rheumatoid arthritis.